Fibromuscular dysplasia of the renal arteries. Literature review
https://doi.org/10.18705/1607-419X-2025-2508
EDN: BBVNGA
Abstract
This article discusses the main issues related to the choice of tactics for the treatment of patients with fibromuscular dysplasia of the renal arteries. The key messages of the Russian, European and American consensus papers are presented. The current concepts of the etiology, risk factors, genetic predictors, as well as management approaches, including surgical treatment, are highlighted.
Keywords
fibromuscular dysplasia of the renal arteries,
renovascular arterial hypertension,
endovascular surgery,
secondary arterial hypertension
Supporting agencies: The work was supported by the Almazov National Medical Research Center.
About the Authors
S. V. Kogay
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Sergey V. Kogay - MD, Cardiologist, Department of Cardiovascular Surgery No. 2, Assistant, Department of Therapy with the Clinic, Medical Faculty, Institute of Medical Education, Almazov National Medical Research Center.
2 Akkuratov str., St Petersburg, 197341
N. G. Avdonina
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Natalya G.Avdonina - MD, Researcher, Research Laboratory of Pathogenesis and Treatment of Hypertension, Research Department for Hypertension, Institute of Heart and Blood Vessels, Head, Department of Information Support and Telemedicine, Department for the Implementation of Federal Projects, Almazov National Medical Research Center.
St Petersburg
Yu. K. Panteleeva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Yulia K. Panteleeva - MD, Junior Researcher, Research Institute of Vascular and Interventional Surgery, Cardiovascular Surgeon, Department of Cardiovascular Surgery No. 2, Almazov National Research Center.
St Petersburg
M. A. Chernyavsky
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Mikhail A. Chernyavsky - MD, PhD, DSc, Head, Research Institute of Vascular and Interventional Surgery, Cardiovascular Surgeon, Associate Professor, Department of Specialized Surgery with the Clinic, Almazov National Medical Research Center.
St Petersburg
A. O. Konradi
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Aleksandra O. Konradi - MD, PhD, DSc, Professor, Academician of the Russian Academy of Sciences, Deputy Director General for Scientific Work, Head, Department of Organization, Management and Economics of Healthcare, Faculty of Postgraduate and Additional Education, Institute of Medical Education, Almazov National Medical Research Center.
St Petersburg
References
1. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24(2):164–189. https://doi.org/10.1177/1358863X18821816
2. Grishkevich AA, Revishvili ASh, Zotikov AE, Pokrovskii AV, Adyrkhaev ZA, Alekyan BG, et al. Renal Vascular Surgery. M.: Fund ‘Russian Knights’, 2021. 300 p. (In Russ.)
3. Plouin PF, Baguet JP, Thony F, Ormezzano O, Azarine A, Silhol F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). Hypertension. 2017;70(3):652–58. https://doi.org/10.1161/HYPERTENSIONAHA.117.09539
4. Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al. The United States Registry for fibromuscular dysplasia: results in the first 447 patients. Circulation. 2012;125(25): 3182–90. https://doi.org/10.1161/CIRCULATIONAHA.112.091223
5. Pappaccogli M, Di Monaco S, Warchoł-Celińska E, Lorthioir A, Amar L, Aparicio LS, et al. The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovasc Res. 2021;117(3):950–959. https://doi.org/10.1093/cvr/cvaa102
6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339
7. Lenz T. Behandlung der Nierenarterienstenose im Jahr 2021. [Treatment of renal artery stenosis in the year 2021]. Internist (Berl). 2021;62(3):252–62. https://doi.org/10.1007/s00108-020-00935-5
8. Idrisov IA, Khafizov TN, Khafizov RR, Shaymuratov IKh, Abhalikova EE, Idrisova LR. Renal artery stenosis, diagnosis and management: a literature review. creative surgery and oncology. 2021;11(3):235–243. (In Russ.) https://doi.org/10.24060/2076-3093-2021-11-3-235-243
9. Rana MN, Al-Kindi SG. Prevalence and manifestations of diagnosed fibromuscular dysplasia by sex and race: analysis of > 4500 FMD cases in the United States. Heart Lung. 2021;50(1):168–173. https://doi.org/10.1016/j.hrtlng.2020.09.022
10. Persu A, Van der Niepen P, Touzé E, Gevaert S, Berra E, Mace P, et al. Revisiting fibromuscular dysplasia: rationale of the european fibromuscular dysplasia initiative. Hypertension. 2016;68(4):832–9.
11. Chazova IE, Chikhladze NM, Blinova NV, Belaya ZE, Danilov NM, Elfimova EM, et al. Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022). Eurasian Heart Journal. 2023;(1):6–65. (In Russ.) https://doi.org/10.38109/2225-1685-2023-1-6-65
12. Shchelkova GV, Danilov NM, Erkenova AM, Yarovoy SYu, Matchin YuG, Mironova OYu, et al. Consensus on renovascular hypertension: diagnosis and treatment. Systemic Hypertension. 2023;20(2):5–20. (In Russ.) https://doi.org/10.38109/2075-082X-2023-2-5-20
13. Baradhi KM, Bream P. Fibromuscular dysplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021
14. Shivapour DM, Erwin P, Kim ESh. Epidemiology of fibromuscular dysplasia: A review of the literature. Vasc Med. 2016;21(4):376–81. https://doi.org/10.1177/1358863X16637913
15. Wu HHL, Damle A, Chinnadurai R, Chrysochou C. Lessons for the clinical nephrologist: fibromuscular dysplasia in older adults. J Nephrol. 2025;38(1):283–288. https://doi.org/10.1007/s40620-024-02039-x
16. Leadbetter WF, Burkland CE. Hypertension in unilateral renal disease. J Urol. 1938;39:611–26. https://doi.org/10.1016/S0022-5347(17)71895-2
17. McCormack LJ, Hazard JB, Poutasse EF. Obstructive lesions of the renal artery associated with remediable hypertension. Am J Pathol.1958;34:582.
18. Harrison EG, Jr McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc. 1971;46:161–7.
19. Chrysant SG, Chrysant GS. Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries. Cardiovasc Diagn Ther. 2014;4(1):36–43. https://doi.org/10.3978/j.issn.2223-3652.2014.02.01
20. Akiba Y, Endo A, Suzuki K, Hoshino Y, Suzuki T, Fujii Y. Fibromuscular dysplasia of coronary and brachial artery. Can J Cardiol. 2018;34(12):1689.e3–1689.e4. https://doi.org/10.1016/j.cjca.2018.09.002
21. Babapoor-Farrokhran S, Port Z. Fibromuscular dysplasia involving the coronary arteries. Methodist Debakey Cardiovasc J. 2021;17(1):71–72. https://doi.org/10.14797/OYIY5154
22. Ko M, Kamimura K, Sakamaki A, Niwa Y, Tominaga K, Mizuno K, et al. Rare mesenteric arterial diseases: fibromuscular dysplasia and segmental arterial mediolysis and literature review. Intern Med. 2019;58(23):3393–3400. https://doi.org/10.2169/internalmedicine.3094-19
23. Okazaki J, Guntani A, Homma K, Kyuragi R, Kawakubo E, Maehara Y. Fibromuscular dysplasia of the lower extremities. Ann Vasc Dis. 2011;4(2):143–9. https://doi.org/10.3400/avd.cr.10.01027
24. Antonescu I, Knowles M, Wirtz E, Pascarella L.An unusual case of bilateral upper extremity ischemia caused by forearm vessel fibromuscular dysplasia. Ann Vasc Surg. 2019;56:353.e7–353.e11. https://doi.org/doi.org/10.1016/j.avsg.2018.08.110
25. Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X. Fibromuscular dysplasia. Orphanet J Rare Dis. 2007;2:28. https://doi.org/10.1186/1750-1172-2-28
26. Gladstien K, Rushton AR, Kidd KK. Penetrance estimates and recurrence risks for fibromuscular dysplasia. Clin Genet. 1980;17(2):115–6. https://doi.org/10.1111/j.1399-0004.1980.tb00117.x
27. Ganesh SK, Morissette R, Xu Z, Schoenhoff F, Griswold BF, Yang J, et al. Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF-β expression and connective tissue features. FASEB J. 2014;28:3313– 3324. https://doi.org/10.1096/fj.14-251207
28. Kiando SR, Tucker NR, Castro-Vega LJ, Katz A, D’Escamard V, Tréard C, et al. PHACTR1 is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance. PLoS Genet. 2016;12(10): e1006367. https://doi.org/10.1371/journal.pgen.1006367
29. Shimabukuro M. A new plausible link between lysophosphatidylcholine, TGF-β, and fibromuscular dysplasia. J Atheroscler Thromb. 2016;23(6):665–7. https://doi.org/10.5551/jat.ED040
30. Petropoulos T, Shah A, Dueck A, Hawkes C, Tobe SW, Kingston W, et al. Fibromuscular dysplasia: a focused review for the cardiologist. CJC Open. 2024;6(11):1274–1288. https://doi.org/10.1016/j.cjco.2024.07.014
31. Sharma AM, Kline B. The United States registry for fibromuscular dysplasia: new findings and breaking myths. Tech Vasc Interv Radiol. 2014;17(4):258–63. https://doi.org/10.1053/j.tvir.2014.11.007
32. Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U. S. Registry for FMD. J Am Coll Cardiol. 2016;68(2):176–85. https://doi.org/10.1016/j.jacc.2016.04.044
33. Bloch MJ, Basile J. Clinical insights into the diagnosis and management of renovascular disease. An evidence-based review. Minerva Med. 2004;95(5):357–73
34. O’Connor S, Gornik HL, Froehlich JB, Gu X, Gray BH, Mace PD, et al. Smoking and adverse outcomes in fibromuscular dysplasia: U. S. Registry report. J Am Coll Cardiol. 2016;67(14): 1750–1. https://doi.org/10.1016/j.jacc.2016.01.058
35. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71: e13-e115. https://doi.org/10.1161/HYP.0000000000000065
36. Zeller T. Renal artery stenosis: epidemiology, clinical manifestation, and percutaneous endovascular therapy. J Interv Cardiol. 2005;18(6):497–506. https://doi.org/10.1111/j.1540–8183.2005.00092.x
37. Warchol-Celinska E, Prejbisz A, Dobrowolski P, Klisiewicz A, Kadziela J, Florczak E, et al. Systematic and multidisciplinary evaluation of fibromuscular dysplasia patients reveals high prevalence of previously undetected fibromuscular dysplasia lesions and affects clinical decisions: the ARCADIA-POL study. Hypertension. 2020;75(4):1102–1109. https://doi.org/10.1161/HYPERTENSIONAHA.119.13239
38. Wang LC, Scott DJ, Clemens MS, Hislop SJ, Arthurs ZM. Mechanism of stent failure in a patient with fibromuscular dysplasia following renal artery stenting. Ann Vasc Surg. 2015;29(1):123. e19–21. https://doi.org/10.1016/j.avsg.2014.08.002
39. Kądziela J, Jóźwik-Plebanek K, Pappaccogli M, van der Niepen P, Prejbisz A, Dobrowolski P, et al. Risks and benefits of renal artery stenting in fibromuscular dysplasia: lessons from the ARCADIA-POL study. Vasc Med. 2024;29(1):50–57. https://doi.org/10.1177/1358863X231210523
40. Cadour F, Silhol F, Iline N, Giorgi R, Lorthioir A, Amar L, et al. Insights from intravascular pressure measurement of renal artery revascularization in patients with fibromuscular dysplasia: The DYSART study. J Vasc Surg. 2022;75(3):939–49. e1. https://doi.org/10.1016/j.jvs.2021.09.023
41. Meuse MA, Turba UC, Sabri SS, Park AW, Saad WE, Angle JF, et al. Treatment of renal artery fibromuscular dysplasia. Tech Vasc Interv Radiol. 2010;13(2):126–33. https://doi.org/10.1053/j.tvir.2010.02.007
42. Sciacca L, Ciocca RG, Eslami MH, Messina LM. Endovascular treatment of renal artery aneurysm secondary to fibromuscular dysplasia: a case report. Ann Vasc Surg. 2009;23(4):536. e9–12. https://doi.org/10.1016/j.avsg.2008.11.011
43. Yakovleva EV, Voloshinova EV, Tyapkina MA, Makhina VI. Effectiveness of balloon angioplasty in the treatment of fibromuscular dysplasia of the renal arteries (10-year follow-up). Therapy. 2023;9(3):136–40. (In Russ.) https://dx.doi.org/10.18565/therapy.2023.3.136-140
44. Itani HS, Mudawwar WA, Tanios BY, Alam SE, Haddad FF. First use of a drug-eluting balloon in the treatment of acute renal artery occlusion and in-stent restenosis. Am J Med Sci. 2013;346(3):244–6. https://doi.org/10.1097/MAJ.0b013e31828b2b7f
45. Hecht T, Esmaeili A, Behnke-Hall K. Balloon angioplasty of the bilateral renal arteries by Takayasu arteritis with a paclitaxeleluting balloon. Cardiol Young. 2015;25(7):1431–4. https://doi.org/10.1017/S1047951114001930
46. Li X, Zhang J, Meng Y, Yang L, Wang F, Li B, et al. Transplant renal artery stenosis caused by the stretch of an artery branch: a case report and literature review. BMC Nephrol. 2018;19(1):56. https://doi.org/10.1186/s12882-018-0856-y
47. Shukurov FB, Taliuridze MT, Kharlap MS, Kardashova MA, Fedotova NP, Vasiliev DK, et al. Treatment of renal artery fibromuscular dysplasia with drug-eluting balloon angioplasty and intravascular imaging: a case report. Russian Journal of Cardiology. 2024;29(2S):5774. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5774
48. Song X, Fu Y, Lai Z, Di X, Zeng R, Shao J, et al. Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study. BMC Cardiovasc Disord. 2023;23(1):510. https://doi.org/10.1186/s12872-023-03484-5
49. Gavalas MV, Gasparis AP, Tassiopoulos AK, Loh S, Labropoulos N. Long-term follow-up for percutaneous transluminal angioplasty in renal artery fibromuscular dysplasia. Int Angiol. 2015;34(6):529–37.
50. Fujihara M, Fukata M, Higashimori A, Nakamura H, Odashiro K, Yokoi Y. Short- and mid-term results of balloon angioplasty for renal artery fibromuscular dysplasia. Cardiovasc Interv Ther. 2014;29(4):293–9. https://doi.org10.1007/s12928-014-0253-9
51. Brekke IB, Sødal G, Jakobsen A, Bentdal O, Pfeffer P, Albrechtsen D, et al. Fibro-muscular renal artery disease treated by extracorporeal vascular reconstruction and renal autotransplantation: short- and long-term results. Eur J Vasc Surg. 1992;6(5):471–6. https://doi.org/10.1016/s0950-821x(05)80619-x
52. Goodman J, Kulkarni S, Selvarajah V, Hilliard N, Russell N, Wilkinson IB. Renal autotransplantation for uncontrolled hypertension in nonatherosclerotic renal artery stenosis-2 case reports and a brief review of the literature. Hypertension. 2024;81(4):669– 675. https://doi.org/10.1161/HYPERTENSIONAHA.123.19878
Supplementary files
Review
For citations:
Kogay S.V., Avdonina N.G., Panteleeva Yu.K., Chernyavsky M.A., Konradi A.O. Fibromuscular dysplasia of the renal arteries. Literature review. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2025;31(2):115-124. (In Russ.) https://doi.org/10.18705/1607-419X-2025-2508. EDN: BBVNGA
Views:
12
Email this article 